CBD (cannabidiol) for early psychosis
Treatments studied
Part of Mental health clinical trials.
This study tests if adding a CBD medication to your current antipsychotic can improve symptoms in people with schizophrenia or related disorders who started treatment recently but aren't fully better yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 16 to 40 years
- Currently taking an antipsychotic for at least 3 weeks, but no more than 16 weeks
- Your current antipsychotic isn't working well enough and your doctor agrees it's safe to add the study drug
- Diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder
- Not in remission from your psychosis symptoms
- Willing to use highly effective birth control if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a cannabis-based medicine called cannabidiol (CBD) to clozapine helps people with early psychosis who still have symptoms. It may improve your symptoms and overall well-being.
This trial tests a special clinic that helps people with a first episode of psychosis cut down or stop using cannabis. The clinic provides talking support and practical help, and the goal is to improve your mental health and quality of life.
This Phase 1 study tests whether adding memantine can improve “negative symptoms” (like low motivation, reduced emotional expression) in people having their first episode of psychosis. It’s designed to understand safety and early effects when dopamine-related treatment is adjusted.
This study tests whether a medication called cannabidiol (a non-intoxicating compound from cannabis) can help reduce symptoms and prevent progression in young people at clinical high risk for psychosis. Participants will receive either the study drug or a placebo (a pill with no active ingredient) and will be followed to see how they respond.
This Phase 3 trial tests whether taking cannabidiol (CBD) can reduce symptoms when added to standard care for early psychosis (like first-episode psychosis or attenuated psychosis). It may help some people have fewer troubling thoughts or perceptions over time.
This trial tests whether cannabidiol (CBD) can reduce symptoms of bipolar depression. You may be eligible if you have bipolar I or II and a current depressive episode while staying on approved mood-stabilizing or antipsychotic medication.
Hear when a new Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.